Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Pulmatrix Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Peter Ludlum

İcra Kurulu Başkanı

US$510.2k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Recent updates

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Aug 02

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

CEO

Peter Ludlum (69 yo)

less than a year

Görev süresi

US$510,224

Tazminat

Mr. Peter B. Ludlum, CMA, MBA, served as Interim Chief Financial Officer and Principal accounting & financial officer at Pulmatrix, Inc. since April 18, 2022 until July 20, 2024 and also serves as its Inte...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Higgins	Independent Chairman	9.3yrs	US$92.97k	0% $ 0
David Denning	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
Christopher Cabell	Independent Director	4.3yrs	US$50.56k	0% $ 0
Jonathan Corren	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
Richard Batycky	Independent Director	4.9yrs	US$59.56k	0.00068% $ 52.4
Todd Bazemore	Independent Director	4yrs	US$58.06k	0% $ 0
Ritesh Agarwal	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
Cendrine Godet	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
David Stevens	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
Michael Wechsler	Member of Pulmazole Clinical Advisory Board	no data	Veri yok	Veri yok
William Calhoun	Chair of PUR1900 & PUR1800 Clinical Advisory Board	no data	Veri yok	Veri yok
Stephen Silberstein	Chair of PUR3100 (DHE) Clinical Advisory Board	no data	Veri yok	Veri yok

4.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PULM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

Pulmatrix Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Recent updates

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş